About this project

EMPIR_logo

——————————————————————————————————————————————-
UPDATE: Presentations from the first scientific workshop for stakeholders (Vienna, 5-6 April 2017) are available for download here.
——————————————————————————————————————————————-

Metrology for clinical implementation of dosimetry in molecular radiotherapy (MRTDosimetry) is a joint research project (JRP) within the European Metrology Programme for Innovation and Research (EMPIR). It brings together expertise in metrology and nuclear medicine research in order to address the problem of determining the radiation dose to individual patients who are undergoing molecular radiotherapy (MRT), also known as 'targeted radionuclide therapy', or 'nuclear medicine therapy'. The project began on 1 June 2016 and will run for three years, finishing on 31 May 2019.

The overall aim of the project is to provide the metrology for the clinical implementation of absorbed dose calculations in MRT. The project builds on the results and outputs from the preceding EMRP JRP HLT11 MetroMRT project, which took the first steps towards providing data, methods, protocols and guidance for MRT dosimetry in collaboration with many European MRT clinics as well as radiopharmaceutical companies and camera manufacturers. The focus of this follow-on project is “clinical implementation” and it is strongly directed by the involvement of leading MRT clinics across Europe as well as building on metrology expertise.

The specific objectives of this project are:

  1. To determine branching ratios and emission probabilities for Y-90 and Ho-166 in order to enable improved quantitative imaging (QI) accuracy and dose estimation for these radionuclides, and to exploit new technologies in order to develop a suitable transfer instrument optimised for accuracy of measurements of the activity of MRT agents in clinics and radiopharmaceutical companies.
  2. To develop 3D printing methods in order to generate a range of quasi-realistic anthropomorphic phantoms containing compartments fillable with known activities of radioactive liquid or standardised sealed radioactive test sources, having a range of geometrical complexity for validation of multimodal QI or absorbed dose measurement, and estimation of the uncertainties of measurement. 
  3. To generate multimodal images either from SPECT or PET-CT phantom measurements or Monte Carlo (MC) simulations to provide material for an open-access database of reference images to be used as reference data for commissioning and Quality Control (QC) of QI using SPECT or PET-CT. 
  4. To improve the accuracy and metrological traceability in the calculation of dose from time-sequences of QI measurements by optimisation of the time points (i.e. obtaining cumulated activity from a time-activity-curve (TAC)), choice of measurement modality (imaging or non-imaging), refinement of absorbed dose standards, and validation of alternative absorbed dose calculation methods in phantoms using physical measurement techniques.
  5. To determine uncertainties in relation to the full MRT dose measurement chain from a primary standard to a range of commercial and non-commercial dosimetry calculation platforms.
  6. To facilitate the take up by healthcare professionals (clinical centres) and industry (scanner manufacturers and software developers) of the technology and measurement infrastructure developed by the project.
     

Download Publishable SummaryAdobe Acrobat file of this project.
Download Final Publishable JRP ReportAdobe Acrobat file of the preceding project MetroMRT.

More detailed results from reports internal to the project may be made available to individual enquirers.